Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 4/20 | 0.39 |
| ▸ | DGKA | P23743 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 5/20 | 0.33 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.33 |
| ▸ | CTSG | P08311 | 1/20 | 0.33 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.33 |
| ▸ | CMA1 | P23946 | 1/20 | 0.33 |
| ▸ | PAM | P19021 | 2/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.32 |
| ▸ | FAAH | O00519 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19863302 | 0.97 | ALDH1A1 (0.43) | ALDH1A1TSHRDGKALMNAPRSS1 | |
| SCHEMBL6887378 | 0.97 | ALDH1A1 (0.43) | ALDH1A1TSHRDGKALMNAPRSS1 | |
| SCHEMBL3173473 | 0.91 | ALDH1A1 (0.48) | ALDH1A1TSHRDGKALMNAPRSS1 | |
| SCHEMBL25304019 | 0.88 | ALDH1A1 (0.54) | ALDH1A1TSHRDGKALMNAPAM | |
| SCHEMBL28812961 | 0.86 | DGKA (0.57) | ALDH1A1TSHRDGKALMNAPAM | |
| SCHEMBL27238986 | 0.86 | DGKA (0.57) | ALDH1A1TSHRDGKALMNAPAM | |
| SCHEMBL27277210 | 0.83 | PTGS1 (0.41) | ALDH1A1TSHRDGKALMNAPAM | |
| SCHEMBL27895346 | 0.82 | MGAM (0.43) | ALDH1A1TSHRDGKALMNAPAM | |
| SCHEMBL2789194 | 0.81 | ALDH1A1 (0.50) | ALDH1A1TSHRLMNAPRSS1CTSG | |
| SCHEMBL3173479 | 0.79 | ALDH1A1 (0.71) | ALDH1A1TSHRDGKALMNAPAM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12636371-B2 | Chemically coupled transporter for low-hydrophobicity bioactive drugs into the central nervous system | SKYBIO LLC (US) | 2026-05-26 | — | — | US | disclosed |
| EP-4271415-B1 | CHEMICALLY COUPLED TRANSPORTER FOR DOPAMINE INTO THE CENTRAL NERVOUS SYSTEM | SKYBIO LLC (US) | 2024-07-03 | — | — | EP | disclosed |
| US-20240197892-A1 | Chemically Coupled Transporter for Low-Hydrophobicity Bioactive Drugs into the Central Nervous System | UNIVERSIDAD DE BUENOS AIRES (AR) | 2024-06-20 | — | — | US | disclosed |
| US-11951170-B2 | Chemically coupled transporter for low-hydrophobicity bioactive drugs into the central nervous system | SKYBIO LLC (US) | 2024-04-09 | — | — | US | disclosed |
| EP-4271415-A1 | CHEMICALLY COUPLED TRANSPORTER FOR LOW-HYDROPHOBICITY BIOACTIVE DRUGS INTO THE CENTRAL NERVOUS SYSTEM | Skybio LLC (US) | 2023-11-08 | — | — | EP | disclosed |
| US-20230218768-A1 | Chemically Coupled Transporter for Low-Hydrophobicity Bioactive Drugs into the Central Nervous System | CONSEJO NACIONAL DE INVESTIGACIONES CIENTÍFICAS Y TÉCNICAS (CONICET) (AR) | 2023-07-13 | — | — | US | disclosed |
| WO-2022167954-A1 | CHEMICALLY COUPLED TRANSPORTER FOR LOW-HYDROPHOBICITY BIOACTIVE DRUGS INTO THE CENTRAL NERVOUS SYSTEM | SKYBIO LLC (US) | 2022-08-11 | — | — | WO | disclosed |
| US-9217109-B2 | Polymer-stabilised liquid-crystal media and displays | MERCK PATENT GMBH (DE) | 2015-12-22 | — | — | US | disclosed |
| US-20130119311-A1 | POLYMER-STABILISED LIQUID-CRYSTAL MEDIA AND DISPLAYS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230218768-A1 | Chemically Coupled Transporter for Low-Hydrophobicity Bioactive Drugs into the Central Nervous System | SLC6A3, SLC18A2, TSPO | ALDH1A1 2823/4885TSHR 1795/4885DGKA 2250/4885 |
| US-20240197892-A1 | Chemically Coupled Transporter for Low-Hydrophobicity Bioactive Drugs into the Central Nervous System | SLC6A3, SLC18A2, TSPO | ALDH1A1 2823/4885TSHR 1795/4885DGKA 2250/4885 |
| US-11951170-B2 | Chemically coupled transporter for low-hydrophobicity bioactive drugs into the central nervous system | SLC7A1, SLC47A2, ABCB1 | ALDH1A1 1921/4885TSHR 2141/4885DGKA 3349/4885 |
| US-12636371-B2 | Chemically coupled transporter for low-hydrophobicity bioactive drugs into the central nervous system | SLC6A2, SLC6A3, SLC18A2 | ALDH1A1 1700/4885TSHR 1144/4885DGKA 4347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.